Characteristics of the First 102 Severe COVID-19 Cases Treated With Convalescent Plasma or Tocilizumab or Both in Al-Nahdha Hospital, Oman.

Al Harthi, Saud; Osali, Magdi Al; Kindi, Nasser Al; Kharusi, Zahir Al; Qasabi, Salim Al; Hinai, Mohamed Al; Ghafri, Thamra Al

Al Harthi, Saud; Osali, Magdi Al; Kindi, Nasser Al; Kharusi, Zahir Al; Qasabi, Salim Al; Hinai, Mohamed Al; Ghafri, Thamra Al.

Afiliación

Al Harthi S; Al-Nahdha Hospital_Department of Medicine, Oman Ministry of Health, Muscat, Oman.
Osali MA; Al-Nahdha Hospital_Department of Medicine, Oman Ministry of Health, Muscat, Oman.
Kindi NA; Al-Nahdha Hospital_Department of Medicine, Oman Ministry of Health, Muscat, Oman.
Kharusi ZA; Al-Nahdha Hospital_Department of Medicine, Oman Ministry of Health, Muscat, Oman.
Qasabi SA; Al-Nahdha Hospital_Department of Medicine, Oman Ministry of Health, Muscat, Oman.
Hinai MA; Al-Nahdha Hospital_Department of Medicine, Oman Ministry of Health, Muscat, Oman.
Ghafri TA; Planning and Studies_Muscat Region, Oman Ministry of Health, Muscat, Oman.

Health Serv Res Manag Epidemiol ; 8: 2333392820986639, 2021.

Article en En | MEDLINE | ID: mdl-33623809

Palabras clave

Covid-19; Oman; characteristics; clinical; convalescent plasma; tocilizumab

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: Health Serv Res Manag Epidemiol Año: 2021 Tipo del documento: Article País de afiliación: Omán Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google